How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Raje and Dr. O'Donnell discuss the combination of monoclonal antibody therapies targeting the PD-1 receptor with approved therapies such as pomalidomide to treat multiple myeloma.
Dr. Raje, Dr. Yee and Dr. O'Donnell discuss various daratumumab combinations that have emerged as options for the treatment of multiple myeloma.
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple myeloma who have received one prior line of therapy.
Dr. Raje and Dr. O'Donnell look at a study that proves there is a role for salvage autologous stem cell transplantation in the second-line setting for multiple myeloma patients.
Dr. O'Donnell and Dr. Raje look at a study that attempts to understand the biology of clonal plasma cells in low levels or MRD states after induction therapy, which can lead to a better understanding of chemoresistance and more effective therapies for MM.
Drs. Raje and O'Donnell shed light on the use of chimeric antigen receptor (CAR) T cells for the treatment of multiple myeloma.
Drs. Raje, O'Donnell, and Yee discuss progress in drugs for the treatment of multiple myeloma, especially immuno-oncology and monoclonal antibodies (MoABs).
Dr. Raje and Dr. O'Donnell take a look at the use of magnetic resonance imaging in the diagnostic evaluation of multiple myeloma, in order to better manage these diseases.
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology